Targeting STAT3 in cancer immunotherapy
According to the FDA prescribing information for Zepbound, the most common gastrointestinal adverse reactions in the SURMOUNT clinical trials included nausea (24-30%), diarrhea (18-24%), vomiting (8-12%), constipation (16-17%), dyspepsia (5-9%), and abdominal pain (6-10%), with rates varying by dose
As adoption continues to accelerate, it will be increasingly important to address the broader physiological changes many patients experience throughout treatment, not just medication access
4) Ingredient transparency: the shorter and clearer, the better
Nonetheless, the underlying reasons for the inconsistencies in the reported associations between T2DM and levels of plasma DPP-4 activity (lower, unaltered, higher) have not been adequately explained, although one study did suggest that it might be related to the populations studied, with changes only becoming evident once moderate or severe hyperglycaemia becomes established (68)
,aspect=ignore)
